A
Acumen Pharmaceuticals, Inc. (ABOS)
NMS – Real Time Price. Currency in USD
2.48
-0.09 (-3.50%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.48
-0.09 (-3.50%)
At close: May 12, 2026, 4:00 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.07 | 6.05 | 10 | |
| Quick ratio | 4.07 | 5.63 | 10 | |
| Debt to Equity | 0.44 | 0.30 | 7.0 | |
| Debt to Assets | 0.25 | 1.04 | 7.0 | |
| Interest coverage | -23.18 | -16.91 | 1.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -169K | -184K | -178K | -184K | -184K |
| Operating Income | -45M | -61M | -114M | -124M | -124M |
| Net Income | -43M | -52M | -102M | -121M | -121M |
| EBITDA | -45M | -61M | -114M | -124M | -124M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 16.09 | 5.0 |
| Next quarter | N/A | 41.46 | 5.5 |
| Current year | N/A | 19.38 | 5.0 |
| Next year | N/A | 12.09 | 4.0 |
| Weighted average score | 4.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 4.96 | 9.09 | 37.37 | 7.5 |
| Y/Y | 999 | 32.34 | 35.48 | 29.83 | 10 |
| 3y average | 999 | -45.37 | -25.71 | -52.06 | 3.3 |
| 5y average | 779.2 | -270.43 | 0.43 | -78.79 | 3.5 |
| Weighted average score | 6.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $54.0M significantly exceed its total debt $31.3M, ensuring strong financial flexibility
Total current assets $122.3M exceed Total current liabilities $30.0M, highlighting excellent liquidity
Debt-to-equity ratio (0.4) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-23.2x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$19.1M limits the company's ability to reinvest or pay down debt